| The PI3K pathway in human disease DA Fruman, H Chiu, BD Hopkins, S Bagrodia, LC Cantley, RT Abraham Cell 170 (4), 605-635, 2017 | 2110 | 2017 |
| Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ... Cancer discovery 7 (5), 462-477, 2017 | 867 | 2017 |
| Suppression of insulin feedback enhances the efficacy of PI3K inhibitors BD Hopkins, C Pauli, X Du, DG Wang, X Li, D Wu, SC Amadiume, ... Nature 560 (7719), 499-503, 2018 | 538 | 2018 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 444* | 2021 |
| A secreted PTEN phosphatase that enters cells to alter signaling and survival BD Hopkins, B Fine, N Steinbach, M Dendy, Z Rapp, J Shaw, K Pappas, ... Science 341 (6144), 399-402, 2013 | 399 | 2013 |
| PTEN function: the long and the short of it BD Hopkins, C Hodakoski, D Barrows, SM Mense, RE Parsons Trends in biochemical sciences 39 (4), 183-190, 2014 | 342 | 2014 |
| Obesity and cancer mechanisms: cancer metabolism BD Hopkins, MD Goncalves, LC Cantley Journal of clinical oncology 34 (35), 4277, 2016 | 315 | 2016 |
| Phosphatidylinositol 3-kinase, growth disorders, and cancer MD Goncalves, BD Hopkins, LC Cantley New England Journal of Medicine 379 (21), 2052-2062, 2018 | 253 | 2018 |
| Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a B Fine, C Hodakoski, S Koujak, T Su, LH Saal, M Maurer, B Hopkins, ... Science 325 (5945), 1261, 2009 | 251 | 2009 |
| Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer BD Hopkins, MD Goncalves, LC Cantley Nature Reviews Endocrinology 16 (5), 276-283, 2020 | 214 | 2020 |
| Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro Y Takeda, AR Kazarov, CE Butterfield, BD Hopkins, LE Benjamin, ... Blood 109 (4), 1524-1532, 2007 | 209 | 2007 |
| An atlas of substrate specificities for the human serine/threonine kinome JL Johnson, TM Yaron, EM Huntsman, A Kerelsky, J Song, A Regev, ... Nature 613 (7945), 759-766, 2023 | 168 | 2023 |
| 3-phosphoinositide–dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma M Maurer, T Su, LH Saal, S Koujak, BD Hopkins, CR Barkley, J Wu, ... Cancer research 69 (15), 6299-6306, 2009 | 166 | 2009 |
| Gab2-mediated signaling promotes melanoma metastasis B Horst, SK Gruvberger-Saal, BD Hopkins, L Bordone, Y Yang, ... The American journal of pathology 174 (4), 1524-1533, 2009 | 125 | 2009 |
| Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability Q Xue, B Hopkins, C Perruzzi, D Udayakumar, D Sherris, LE Benjamin Cancer research 68 (22), 9551-9557, 2008 | 113 | 2008 |
| Fenofibrate prevents skeletal muscle loss in mice with lung cancer MD Goncalves, SK Hwang, C Pauli, CJ Murphy, Z Cheng, BD Hopkins, ... Proceedings of the National Academy of Sciences 115 (4), E743-E752, 2018 | 107 | 2018 |
| PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion SM Mense, D Barrows, C Hodakoski, N Steinbach, D Schoenfeld, W Su, ... Science signaling 8 (370), ra32-ra32, 2015 | 73 | 2015 |
| A unified nomenclature and amino acid numbering for human PTEN R Pulido, SJ Baker, JT Barata, A Carracedo, VJ Cid, ID Chin-Sang, ... Science signaling 7 (332), pe15-pe15, 2014 | 68 | 2014 |
| Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis C Hodakoski, BD Hopkins, D Barrows, SM Mense, M Keniry, KE Anderson, ... Proceedings of the National Academy of Sciences 111 (1), 155-160, 2014 | 67 | 2014 |
| Metformin and erlotinib synergize to inhibit basal breast cancer YKI Lau, X Du, V Reyannavar, B Hopkins, J Shaw, E Bessler, T Thomas, ... Oncotarget 5 (21), 10503, 2014 | 63 | 2014 |
Lewis CantleyDana Farber Cancer Center and Harvard Medical SchoolVerified email at med.cornell.edu
